Search

VIRIDIAN THERAPEUTICS INC

Gesloten

SectorGezondheidszorg

22.3 -2.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.85

Max

22.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-22M

-127M

Verkoop

143K

284K

EPS

-1.05

Winstmarge

-44,760.211

Werknemers

252

EBITDA

-17M

-119M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+49.48% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

224M

2.4B

Vorige openingsprijs

24.32

Vorige sluitingsprijs

22.3

VIRIDIAN THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2026, 20:31 UTC

Viridian Therapeutics Inc is seeing a significant decline in after-market trading, deepening its losses since Thursday's close amid unusual weakness.

21 okt 2026, 20:07 UTC

Viridian Therapeutics Inc is trading higher, remaining significantly above its 20-day moving average, despite settling lower after reaching a peak earlier in the session.

20 okt 2026, 20:02 UTC

Viridian Therapeutics Inc shares are advancing, maintaining a sharply higher trajectory since Monday's close despite an earlier pullback from a session high.

19 okt 2026, 20:02 UTC

Viridian Therapeutics Inc shares are sharply higher, continuing a trend of higher daily closes since Friday's close, amid mixed performance in the biotechnology sector.

16 okt 2026, 20:02 UTC

News

Viridian Therapeutics reports positive topline results from its REVEAL-2 Phase 3 trial for elegrobart, but faces increased competition from Roche's FDA-approved Enspryng.

15 okt 2026, 20:02 UTC

Viridian Therapeutics Inc shares are higher, continuing an upward trajectory since Wednesday's close, despite an earlier pullback from a session high.

14 okt 2026, 20:07 UTC

Viridian Therapeutics Inc shares are modestly higher, recovering from an early dip as the broader market also shows gains since Tuesday's close.

12 okt 2026, 20:06 UTC

Viridian Therapeutics Inc shares are declining, retreating from an earlier session high and remaining well below their 20-day moving average amid ongoing weakness.

9 okt 2026, 20:12 UTC

Viridian Therapeutics Inc shares advanced in after-market trading, holding a cumulative return of 1.19% since Friday's close.

8 okt 2026, 20:07 UTC

Viridian Therapeutics Inc shares are slightly higher, recovering from an earlier drop, but remain below their 20-day moving average and near the lower end of their one-month range.

7 okt 2026, 20:21 UTC

Viridian Therapeutics Inc declined during after-market hours, continuing a downward trend that began after Wednesday's close and remaining below its 20-day moving average.

6 okt 2026, 21:03 UTC

Viridian Therapeutics Inc is rising in after-market trading, advancing from a low of roughly flat to a high gain since Tuesday's close.

2 okt 2026, 20:07 UTC

Viridian Therapeutics Inc is advancing in today's trading session, gaining ground since Thursday's close, despite slightly retreating from an early peak.

1 okt 2026, 20:02 UTC

Social Media

Viridian Therapeutics Inc. shares fell sharply amid growing anticipation for a follow-on program, marking a departure from recent higher daily closes.

29 sep 2026, 20:07 UTC

Viridian Therapeutics Inc. shares fell sharply, continuing a decline from Monday's close and remaining near the lower end of their one-month trading range.

25 sep 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, closing lower for the third consecutive session and remaining significantly below the 20-day moving average.

24 sep 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, finishing significantly lower than Wednesday's close and well below its 20-day moving average.

23 sep 2026, 20:12 UTC

Viridian Therapeutics Inc saw modestly lower trading in after-market hours on Wednesday, remaining significantly below its 20-day moving average.

22 sep 2026, 19:34 UTC

News

RBC Capital raised its price target on Viridian Therapeutics to $38, maintaining an Outperform rating, as the stock holds gains above Monday's close despite earlier pulling back.

21 sep 2026, 20:12 UTC

Viridian Therapeutics Inc is trading modestly higher in after-market hours, maintaining stability with no significant movement since Monday's close.

17 sep 2026, 19:46 UTC

News

Viridian Therapeutics Inc shares fell sharply as the company navigates post-FDA approval dynamics for Lumvoa, remaining below its 20-day moving average.

16 sep 2026, 22:01 UTC

Viridian Therapeutics Inc is rising in after-market trading, moving from a low of 1.02% to a high of 1.20% since Wednesday's close.

15 sep 2026, 19:36 UTC

Viridian Therapeutics shares are lower today, continuing a decline since Monday amid broader market pressure from rising treasury yields. No specific news was identified.

14 sep 2026, 20:13 UTC

Viridian Therapeutics Inc. shares are higher in after-market hours, maintaining a cumulative return since Monday's close, despite a weaker performance backdrop.

11 sep 2026, 23:26 UTC

Viridian Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. Recent U.S. inflation data adds broader context.

10 sep 2026, 20:13 UTC

Viridian Therapeutics Inc. shares are higher in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

9 sep 2026, 21:02 UTC

Viridian Therapeutics Inc shares are lower in after-market hours, declining from an initial drop to a more pronounced decrease amid weak trading.

8 sep 2026, 20:13 UTC

Viridian Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain the price movement.

3 sep 2026, 19:16 UTC

News

Viridian Therapeutics will participate in the Wells Fargo Healthcare Conference on September 8, 2026. Shares are slightly higher during Thursday's session.

2 sep 2026, 22:06 UTC

News

Viridian Therapeutics will participate in the Wells Fargo Healthcare Conference on September 8, 2026, with a fireside chat accessible via a live webcast. Shares are little changed.

Peer Vergelijking

Prijswijziging

VIRIDIAN THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

49.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.111 USD  49.48%

Hoogste 41 USD

Laagste 22 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor VIRIDIAN THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

help-icon Live chat